Three different therapies to target PCSK9

Nat Rev Cardiol. 2021 Aug;18(8):541. doi: 10.1038/s41569-021-00581-w.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anticholesteremic Agents* / therapeutic use
  • Cholesterol, LDL
  • Humans
  • Proprotein Convertase 9*

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9